Cognitive behavioural therapy for irritable bowel syndrome:24-month follow-up of participants in the ACTIB randomised trial by Everitt, Hazel A. et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/S2468-1253(19)30243-2
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Everitt, H. A., Landau, S., O'Reilly, G., Sibelli, A., Hughes, S., Windgassen, S., ... Moss-Morris, R. (2019).
Cognitive behavioural therapy for irritable bowel syndrome: 24-month follow-up of participants in the ACTIB
randomised trial. The Lancet Gastroenterology & Hepatology, 4(11), 863-872. https://doi.org/10.1016/S2468-
1253(19)30243-2
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 29. Apr. 2020
www.thelancet.com/gastrohep   Vol 4   November 2019 863
Articles
Cognitive behavioural therapy for irritable bowel syndrome: 
24-month follow-up of participants in the ACTIB 
randomised trial
Hazel A Everitt, Sabine Landau, Gilly O’Reilly, Alice Sibelli, Stephanie Hughes, Sula Windgassen, Rachel Holland, Paul Little, Paul McCrone, 
Felicity L Bishop, Kim Goldsmith, Nicholas Coleman, Robert Logan, Trudie Chalder*, Rona Moss-Morris*
Summary
Background Irritable bowel syndrome (IBS) is common, affecting 10–20% of the adult population worldwide, with 
many people reporting ongoing symptoms despite first-line therapies. Cognitive behavioural therapy (CBT) is 
recommended in guidelines for refractory IBS but there is insufficient access to CBT for IBS and uncertainty about 
whether benefits last in the longer term. Assessing Cognitive behavioural Therapy for IBS (ACTIB) was a large, 
randomised, controlled trial of two forms of CBT for patients with refractory IBS. ACTIB results showed that, at 
12 months, both forms of CBT for IBS were significantly more effective than treatment as usual at reducing IBS 
symptom severity in adults with refractory IBS. This follow-up study aimed to evaluate 24-month clinical outcomes of 
participants in the ACTIB trial.
Methods In the ACTIB three-group, randomised, controlled trial, 558 adults with refractory IBS were randomly 
allocated to receive either therapist-delivered telephone CBT (telephone-CBT group), web-based CBT with minimal 
therapist support (web-CBT group), or treatment as usual (TAU group) and were followed up for 12 months. 
Participants were adults with refractory IBS (clinically significant symptoms for ≥12 months despite being offered 
first-line therapies), recruited by letter and opportunistically from 74 general practices and three gastroenterology 
centres in London and the south of England (UK) between May 1, 2014, and March 31, 2016. Primary outcome 
measures were IBS Symptom Severity Score (IBS-SSS) and Work and Social Adjustment Scale (WSAS), assessed in 
the intention-to-treat (ITT) population with multiple imputation. This study was a non-prespecified naturalistic 
follow-up and analysis of the participants of the ACTIB trial at 24 months assessing the same outcomes as the original 
trial. Outcome measures were completed online by participants or a paper questionnaire was posted, or telephone 
follow-up undertaken. The ACTIB trial is registered with the International Standard Randomised Controlled Trial 
Number registry, number ISRCTN44427879.
Findings 24-month follow-up of outcomes was achieved for 323 (58%) of 558 participants: 119 (64%) of 186 in the 
telephone-CBT group, 99 (54%) of 185 in the web-CBT group, and 105 (56%) of 187 in the TAU group. At 24 months, 
mean IBS-SSS was 40·5 points (95% CI 15·0 to 66·0; p=0·002) lower in the telephone-CBT group and 12·9 points 
(–12·9 to 38·8; p=0·33) lower in the web-CBT group than in the TAU group. The mean WSAS score was 3·1 points 
(1·3 to 4·9; p<0·001) lower in the telephone-CBT group and 1·9 points (0·1 to 3·7; p=0·036) lower in the web-CBT 
group than in the TAU group. A clinically significant IBS-SSS change (≥50 points) from baseline to 24 months was 
found in 84 (71%) of 119 participants in the telephone-CBT group, in 62 (63%) of 99 in the web-CBT group, and in 
48 (46%) of 105 in the TAU group. In total 41 adverse events were reported between 12 to 24 months: 11 in the 
telephone-CBT group, 15 in the web-CBT group, and 15 in the TAU group. Of these, eight were reported as 
gastrointestinal related, five as psychological, and six as musculoskeletal. There were no adverse events related to 
treatment.
Interpretation At 24-month follow-up, sustained improvements in IBS were seen in both CBT groups compared with 
TAU, although some previous gains were reduced compared with the 12-month outcomes. IBS-specific CBT has the 
potential to provide long-term improvement in IBS, achievable within a usual clinical setting. Increasing access to 
CBT for IBS could achieve long-term patient benefit.
Funding UK National Institute for Health Research.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Irritable Bowel Syndrome (IBS) is a common chronic 
gastrointestinal disorder affecting 10–20% of the adult 
population worldwide, with many people having ongoing 
symptoms and incurring substantial health costs.1,2 
Abdominal pain, bloating, and altered bowel habits affect 
quality of life, social functioning, and time off work.3 
Currently, clinicians have few options to offer people 
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with refractory IBS. The National Institute for Health 
and Care Excellence (NICE) guidance3 recommends 
cognitive behavioural therapy (CBT) for patients with 
refractory IBS symptoms (ie, ongoing symptoms after 
12 months despite being offered appropriate medications 
and lifestyle advice). Published trials of CBT for IBS have 
reported promising results at 6 months follow-up after 
randomisation.4,5 However, there is still insufficient 
access to CBT for IBS on the UK National Health Service 
(NHS) and worldwide. Additionally, there is little 
evidence of the longer-term outcomes after CBT for IBS, 
as highlighted in a Cochrane review.6
Assessing Cognitive behavioural Therapy in IBS 
(ACTIB) was a three-group, multicentre, randomised, 
controlled trial (RCT) of two modes of CBT designed 
specifically for IBS (therapist-delivered, telephone CBT 
with a patient self-management manual [telephone CBT] 
and web-based CBT with minimal therapist support [web 
CBT]) compared with treatment as usual (TAU) alone, in 
adults with refractory IBS.7,8 To our knowledge, it is the 
largest RCT of CBT for IBS completed thus far and the 
only one to test the effectiveness of therapist-delivered 
and web-based CBT in the same trial. The ACTIB trial 
results showed that telephone CBT and web CBT were 
significantly more effective than TAU at reducing IBS 
symptom severity and impact on life at 12 months in 
adults with refractory IBS.8 This result was achieved 
within the NHS (CBT-trained NHS therapists delivered 
the interventions).
The aim of the current study was to evaluate longer-
term (24 month) clinical outcomes of telephone CBT 
and web CBT compared with TAU in adults with 
refractory IBS.
Methods
Study design and participants
This study reports a naturalistic 24-month follow-up of 
participants in the ACTIB trial. The ACTIB trial protocol7 
and the trial results8 at 3 months, 6 months, and 
12 months have previously been published.
Participants were people with refractory IBS who were 
randomly allocated to therapist-delivered telephone 
CBT (telephone-CBT group), web-based CBT with 
minimal therapist support (web-CBT group), or TAU 
(TAU group). ACTIB participants were recruited from 
74 primary care general-practice surgeries in the south 
of England and London (UK), and three secondary-care 
gastroenterology outpatient clinics in two regions 
(Southampton University Hospital [Southampton, UK] 
and Guy’s and St Thomas’ Hospital Trust, King’s College 
Hospital [London, UK]) between May 1, 2014, and 
March 31, 2016.
Individuals were eligible if they fulfilled criteria for 
refractory IBS, defined as fulfilling Rome III criteria for 
IBS;9 reported ongoing clinically significant symptoms 
according to the IBS Symptom Severity Score (IBS-SSS;10 
ie, IBS-SSS≥75); had been offered first-line therapies 
(eg, antispasmodics, anti depressants, or fibre-based 
Research in context
Evidence before this study
We searched the PubMed, PsycInfo, and Cochrane Library from 
database inception to Jan 7, 2019, without language restrictions 
for full papers reporting randomised controlled trials, systematic 
reviews, and meta-analyses with the search terms “irritable bowel 
syndrome” and “cognitive behavioural therapy”. We excluded 
trials of adolescents, educational, and group interventions.
Previous research evidence, including several randomised 
controlled trials, suggests that cognitive behavioural therapy 
(CBT) is likely to be helpful for irritable bowel syndrome (IBS) 
in the short term. However, limitations of previous trials include 
small size, high dropout rates from therapy, and lack of 
longer-term follow-up. The UK National Institute for Health and 
Care Excellence guideline for IBS recommends offering CBT for 
people with refractory IBS but acknowledges that further research 
is needed. Currently there is insufficient access to CBT for IBS and 
many patients have no access to psychological therapies for IBS.
The ACTIB trial was, we believe, the largest study of CBT for IBS 
worldwide to date, recruiting 558 participants with 12-month 
follow-up. At 12 months, important clinically and statistically 
significant benefits in IBS symptoms and impact on life were 
found for both telephone-delivered and web-based CBT 
interventions compared with treatment as usual.
Added value of this study
This follow-up study provides a 24-month, naturalistic 
follow-up of the ACTIB participants. Participants received no 
further therapist input but both CBT intervention groups had 
sustained improvement in the primary and secondary 
outcomes at 24 months. This improvement was achieved in a 
clinical setting with relatively modest amounts of therapist 
contact time.
Implications of all the available evidence
This longer follow-up of a large randomised controlled trial 
adds robust data to the evidence base indicating that 
IBS-specific CBT has the potential to provide substantial 
long-term improvement in IBS symptoms, functional 
impairment, and mood and is achievable within a usual clinical 
setting. Both the higher-intensity therapist-delivered telephone 
CBT and the web-based CBT with minimal therapist support 
can achieve significant clinically important improvements at 
24 months. This trial reinforces NICE guidance, which relied on 
a small evidence base, that CBT for IBS has the potential to 
benefit patients with refractory IBS and should be made more 
widely available for this patient group.
For the ACTIB trial protocol see 
https://bmjopen.bmj.com/
content/5/7/e008622
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medications); and had had IBS symptoms for 12 months 
or longer.
Medical exclusion criteria7,8 were unexplained rectal 
bleeding or weight loss, inflammatory bowel disease, 
coeliac disease, peptic ulcer disease, and colorectal 
carcinoma. Additionally, patients were excluded if they 
were younger than 18 years, were unable to participate in 
CBT because of speech or language difficulties, had no 
access to an internet-connected computer, had received 
CBT in the previous 2 years, had had previous access to 
the web CBT for IBS intervention (Regul8) during the 
Management of Irritable Bowel Syndrome in Primary 
Care (MIBS) trial, or were currently participating in 
another IBS intervention trial.
A patient and public involvement (PPI) representative 
participated in the trial management group and was 
included in all phases of trial design, including planning 
recruitment and recruitment materials. They had been a 
participant in the MIBS feasibility study11 and thus were 
able to provide first-hand insight into the burden of the 
intervention and the time required to participate in the 
research. The CBT interventions were developed with 
PPI input.11 The independent trial steering committee 
included another PPI member.
Ethical approval was given by the National Research 
Ethics Service Committee South Central—Berkshire on 
June 11, 2013 (reference number 13/SC/0206). Additional 
online informed consent was obtained from participants 
for the 24-month follow-up.
Procedures
Two active interventions were assessed in the ACTIB 
study: therapist-delivered telephone CBT with a detailed 
patient self-management manual and a low intensity web-
based CBT in the form of the Regul8 program developed 
in the MIBS trial,11 with some therapist support. All groups 
received TAU, with control being TAU alone.
The core CBT content of the two treatment groups was 
similar, based on an empirical cognitive behavioural 
model of IBS12 and versions of this model tested in 
previous smaller RCTs.13,14 It consisted of education around 
the brain–gut axis, behavioural techniques to improve 
bowel habits, developing stable healthy eating and exercise 
patterns, addressing unhelpful thoughts, managing stress 
and emotions, focusing on reducing symptoms, and 
preventing relapse. Treatments were standardised by 
provision of therapist training and therapist manuals. All 
therapists were available to work in both therapy groups 
(telephone-CBT and web-CBT groups) and with any 
participant regardless of recruit ment centre.
Participants randomised to the telephone-CBT group 
received a detailed self-management CBT manual 
including homework tasks and recording sheets and 
were offered six 1-h telephone sessions with a CBT 
therapist at week 1, 2, 3, 5, 7, and 9. They also received 
two 1-h booster sessions at 4 months and 8 months 
(a total of 8 h of therapist support).
Participants in the web-CBT group received three 
30-min therapy-support telephone calls at weeks 1, 3, and 
5 and two 30-min booster sessions at 4 months and 
8 months (2·5 h of therapist support).
TAU was defined as continuation of current medications, 
which varied from patient to patient, and usual general 
practitioner or consultant follow-up with no psychological 
therapy. All general practice or secondary-care sites 
involved in the study received a hard copy (delivered by the 
research team or by post) or a digital copy (delivered by 
email) of the NICE guidance for IBS3 to ensure all 
clinicians had standard best-practice information on IBS 
management. They also received information to remind 
them of the guidelines, protocol guidance on prescribing 
psychological therapies, and inclusion criteria. All 
participants received a standard information sheet on 
lifestyle and diet in IBS based on NICE guidance.3
At 12 months, information was collected on any 
changes in IBS treatments and management during the 
study and numbers of general practitioner and consultant 
consultations were recorded for all three groups.
After the 12-month follow-up assessments, partici pants 
in the TAU group alone were given access to the Regul8 
website (but with no therapy support) via an email link; 
the web-CBT participants also had ongoing access to the 
Regul8 website. Telephone-CBT partici pants were not 
given access to Regul8 but were able to continue to use 
their CBT manuals. Neither CBT group was offered 
further therapist support. Thus, the last contact with a 
trial therapist in the telephone-CBT and web-CBT groups 
was approximately 16 months before the 24 month follow-
up. Participants were free to seek CBT through any 
available means for IBS or any other condition.
13 trained CBT therapists (10 [77%] of whom were 
female; mean age 42 years [range 34–52]) based at South 
London and Maudsley NHS Trust provided the 
telephone CBT sessions for both therapy groups. 
Six (46%) of these therapists were clinical psychologists 
and seven (54%) were cognitive behavioural psycho-
therapists with a median of 7 years (4–24) experience. 
All sessions were audio-recorded for supervision and 
treatment fidelity purposes. Each therapist received a 
therapist manual, 2-day training, and post-training 
supervision. Supervision was done in 90-min group 
sessions every 2 weeks in the first half of the trial, then 
monthly.
Treatment fidelity was further assessed at the end of 
trial by two independent experienced CBT therapists 
using audio-recordings of therapy sessions.
Outcome measures were completed online by partici-
pants at 24 months or a paper copy of the question naires 
was posted or telephone follow-up undertaken as 
described in the protocol7 for the 12-month follow-up.7 
Outcomes
24-month data were collected on the two co-primary 
outcomes from the ACTIB trial,8 IBS-SSS10 and the Work 
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and Social Adjustment Scale (WSAS),14 which measures 
impact of IBS on life including ability to work, manage 
daily home tasks (eg, cleaning, shopping, cooking, child 
care, and paying bills), and participate in social activities.
Data were also collected on the ACTIB trial secondary 
outcome measures at 24 months: Hospital Anxiety and 
Depression Scale (HADS),15 which measures mood as a 
total distress score; Patient Enablement Questionnaire 
(PEQ),16 which measures people’s ability to cope with 
their illness and life after treatment; and Subject’s Global 
Assessment of Relief (SGA),17 which assessed IBS 
symptom relief in a scale of 1–5.
Participants were also asked whether they had sought 
CBT for IBS, CBT for any other condition, or had used 
the web-CBT (ie, the Regul8 website) between the 
12-month and 24-month follow-ups.
Statistical analysis
The statistical analysis of the 24-month outcomes 
followed the analysis approach used to evaluate the 
3-month, 6-month, and 12-month outcomes. Details can 
be found in the published primary trial publication and 
online materials.8 The analysis of the 24-month data was 
not prespecified in the original trial protocol as the 
original trial funding only covered follow-up to 
12 months. We sought an extension to the original trial 
from our funders and the ethics committee and 
participants were asked to provide consent to collect 
24-month data.
Briefly, an intention-to-treat (ITT) approach was used 
for all 24-month outcomes. For each outcome we 
compared the CBT groups (telephone-CBT group or web-
CBT group) with the TAU group to assess treatment 
effectiveness. Modelling of continuous variables 
(IBS-SSS, WSAS, and HADS) relied on normal assump-
tions for error terms and treatment effects were quantified 
by trial-group differences and standardised differences 
(95% CI). The PEQ measure was reclassified as a binary 
variable with a score of 6 or more considered a responder 
to facilitate modelling within a logistic regression 
framework and treatment effects quantified by odds 
ratios (ORs) with 95% CIs.
Telephone-CBT group Web-CBT group TAU group Overall
Number of 
patients
Mean (SD) or 
n (%)
Number of 
patients
Mean (SD) or 
n (%)
Number of 
patients
Mean (SD) or 
n (%)
Number of 
patients
Mean (SD) or 
n (%)
IBS-SSS
Baseline 186 272·3 (95·5) 185 264·2 (99·3) 187 258·5 (91·6) 558 265·0 (95·5)
12 months 136 139·0 (94·8) 124 163·0 (108·8) 131 205·6 (100·5) 391 168·9 (104·8)
24 months 119 164·4 (94·9) 99 167·6 (107·5) 105 197·9 (98·6) 323 176·3 (100·9)
Responders* (12 months) 136 99 (73%) 124 82 (66%) 131 58 (44%) 391 239 (61%)
Responders* (24 months) 119 84 (71%) 99 62 (63%) 105 48 (46%) 323 194 (60%)
WSAS
Baseline 186 12·3 (8·8) 185 13·0 (9·3) 187 12·4 (7·4) 558 12·5 (8·5)
12 months 138 6·0 (7·5) 124 7·4 (7·7) 132 10·8 (9·3) 394 8·1 (8·5)
24 months 118 6·1 (7·6) 99 7·3 (8·0) 105 9·7 (8·5) 322 7·6 (8·1)
HADS
Baseline 186 16·1 (6·9) 185 17·0 (7·3) 187 16·0 (6·4) 558 16·4 (6·9)
12 months 120 12·2 (6·5) 117 12·7 (7·4) 113 15·0 (7·2) 350 13·3 (7·1)
24 months 118 12·1 (6·4) 98 12·2 (7·6) 103 15·1 (6·6) 319 13·1 (7·0)
PEQ†
Non-responders (12 months) 138 30 (22%) 124 56 (45%) 132 101 (77%) 394 187 (47%)
Responders (12 months) 138 108 (78%) 124 68 (55%) 132 31 (23%) 394 207 (53%)
Non-responders (24 months) 119 25 (21%) 99 38 (38%) 103 75 (73%) 321 138 (43%)
Responders (24 months) 119 94 (79%) 99 61 (62%) 103 28 (27%) 321 183 (57%)
SGA†
Non-responders (12 months) 138 21 (15%) 124 31 (25%) 132 77 (58%) 394 129 (33%)
Responders (12 months) 138 117 (85%) 124 93 (75%) 132 55 (42%) 394 265 (67%)
Non-responders (24 months) 45 5 (11%) 35 17 (49%) 44 22 (50%) 124 44 (35%)
Responders (24 months)‡ 45 40 (89%) 35 18 (51%) 44 22 (50%) 124 80 (65%)
CBT=cognitive behavioural therapy. TAU=treatment as usual. IBS–SSS=Irritable Bowel Syndrome Symptom Severity Score. WSAS=Work and Social Adjustment Scale. 
HADS=Hospital Anxiety and Depression Scale. PEQ=Patient Enablement Questionnaire. SGA=Subject’s Global Assessment of Relief. * IBS-SSS responders were defined as 
participants who had a clinically significant change in IBS-SSS (≥50 points) from baseline to 24 months. †PEQ responders are defined as patients achieving a score of 6 or 
more; PEQ was not recorded at baseline. ‡SGA responders are defined as patients achieving a score of 1–3; SGA was not recorded at baseline and was only recorded at 
24 months for participants who completed the outcome measures by paper questionnaire.
Table 1: Descriptive summaries for outcome measures at baseline, 12 months, and 24 months
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Trial groups were compared by multiple imputation 
with the flexible multivariate imputation by chained 
equations approach with 100 imputations.18 This approach 
was necessary because we found that non-adherence with 
treatment was predictive of missing primary outcomes at 
12 months in the CBT groups.8 We also previously 
assessed whether baseline variables were predictive of 
outcome missingness and identified baseline IBS 
symptom severity score and index of multiple deprivation 
(IMD)19 as further possible predictors.8 The linear-
regression or logistic-regression analysis models of the 
multiple-imputation procedure included the respective 
outcome variable as the dependent variable and trial 
group (two dummy variables indicating the telephone-
CBT and web-CBT groups), baseline values of the 
outcome (if available), and randomisation stratifier 
(dummy variables for centres) as explanatory variables. 
Since both telephone-CBT and web-CBT involved 
therapists delivering the intervention, possible therapist 
effects on 24-month outcomes were assessed empirically 
with the same methods as in the primary trial paper.8 
Therapist effects were not detected with an α of 10% and 
so therapist effects were not included in any of the 
24-month analysis models. For each outcome variable, 
the imputation model of the multiple imputation 
procedure included: all variables of the analysis model; 
measures of the outcome variable at other assessment 
timepoints including baseline; and known predictors of 
missingness (ie, binary adherence variables for telephone-
CBT and web-CBT; baseline IBS-SSS; and IMD).
Per-protocol analyses were used to estimate the efficacy 
of telephone-CBT and web-CBT in terms of primary 
outcomes of the original 12-month study. The analyses for 
IBS-SSS and WSAS at 24 months were repeated after 
restricting the sample to those trial participants who: 
adhered to the randomised treatment offered to them 
during the 12-month trial period (adherence to therapy was 
defined as participants in the web-CBT group completing 
at least four website sessions and at least one telephone 
support call or as participants in the telephone-CBT group 
completing at least four of the initial telephone CBT 
sessions);7,8 did not access any form of CBT during the 
12–24-month naturalistic follow-up period; and provided 
24-month outcome data (complete-case approach, no 
imputation). Respective linear regression analyses were 
adjusted for known baseline predictors of missingness at 
12 months (IMD and IBS-SSS).
All analyses were done in Stata, version 14.2.
This study is registered as at the International Standard 
Randomised Controlled Trial Number registry, number 
ISRCTN44427879.
Role of funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had full access to all of the data 
and the corresponding author had the final responsibility 
to submit for publication.
Results
24-month data collection took place between March 1, 2016, 
and May 31, 2018. Among 558 patients who were randomly 
assigned to study groups as part of the ACTIB trial, 
323 (58%) provided data at the 24-month follow-up 
(119 [64%] of 186 in the telephone-CBT group, 99 [54%] of 
185 in the web-CBT group, and 105 [56%] of 187 in the 
Telephone-CBT vs TAU Web-CBT vs TAU
Estimated difference or 
OR* (95% CI)
Test (degrees 
of freedom)
p value Standardised 
difference†
Estimated difference or 
OR* (95% CI)
Test 
(degrees of 
freedom)
p value Standardised 
difference†
IBS-SSS
12 months –62·3 (–90·0 to –34·6) –4·4 (1981) p<0·001 0·65 –35·4 (–58·4 to –12·3) –3·0 (251) 0·003 0·37
24 months –40·5 (–66·0 to –15·0) –3·1 (185) 0·002 0·42 –12·9 (–38·8 to 12·9) –1·0 (178) 0·33 0·14
WSAS
12 months –3·5 (–5·2 to –1·8) –4·2 (257) p<0·001 0·41 –2·9 (–4·5 to –1·3) –3·5 (287) p<0·001 0·34
24 months –3·1 (–4·9 to –1·3) –3·4 (211) p<0·001 0·36 –1·9 (–3·7 to –0·1) –2·1 (213) 0·036 0·22
HADS
12 months –2·8 (–4·1 to –1·4) –4·0 (211) p<0·001 0·40 –2·2 (–3·4 to –0·9) –3·4 (268) 0·001 0·32
24 months –3·1 (–4·7 to –1·6) –4·0 (184) p<0·001 0·46 –2·7 (–4·4 to –1·0) –3·1 (142) 0·002 0·39
PEQ responders
12 months‡ 9·4 (4·5 to 19·7) 5·9 (2510) p<0·001 ·· 3·6 (2·1 to 6·0) 4·7 (775) p<0·001 ·· 
24 months 8·3 (4·2 to 16·4) 6·1 (359) p<0·001 ·· 3·3 (1·8 to 6·0) 3·9 (467) p<0·001 ··
All inferences were derived by multiple imputation as described in the Methods section. Each model used k=100 imputations. CBT=cognitive behavioural therapy. 
TAU=treatment as usual. IBS–SSS=Irritable Bowel Syndrome Symptom Severity Score. WSAS=Work and Social Adjustment Scale. HADS=Hospital Anxiety and Depression 
Scale. PEQ=Patient Enablement Questionnaire. *OR is presented only for PEQ responders. †Differences were standardised by dividing by the respective baseline SDs for 
IBS–SSS (95·5), WSAS (8·8), and HADS (6·9). ‡The 12-month model included therapist effects in the telephone-CBT group, so these effects are conditioned on therapist. 
Table 2: Comparisons between CBT groups and TAU 
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TAU group) compared with 391 (70%) at the 12-month 
follow-up. The mean follow-up time was 638 days (SD 217) 
and the median was 730 days (IQR 730–730).
Table 1 provides descriptive summaries for outcome 
measures at baseline, 12 months, and 24 months. We 
compared the outcomes between each of the CBT groups 
and the TAU group at 12 months and 24 months (table 2). 
Although comparisons at 12 months have been presented 
previously,8 the results shown in table 2 differ slightly 
from those previously published as it was possible to 
incorporate additional information provided by the 
24-month outcomes. This is because multiple imputation 
makes maximum use of all of the available data and is 
adjusted for missing data biases to calculate estimated 
adjusted results. Therefore, including the 24-month data 
affects the estimates for the whole data set.
At 24 months, mean IBS-SSS was 40·5 points (95% CI 
15·0 to 66·0; p=0·002) lower in the telephone-CBT group 
and 12·9 points (–12·9 to 38·8; p=0·33) lower in the 
web-CBT group than in the TAU group, for which mean 
IBS-SSS was 197·9 (SD 98·6; table 1, 2). At 12 months, the 
differences between the therapy versus TAU groups were 
62·3 points lower (34·6 to 90·0; p<0·001) for the 
telephone-CBT group and 35·4 lower (12·3 to 58·4; 
p=0·003) for the web-CBT group. Thus, on the basis of the 
ITT analysis, a significant difference in mean  IBS-SSS 
was sustained at 24 months for the telephone-CBT group 
but not the web-CBT group versus the TAU group.
We predicted mean IBS-SSS from the multiply 
imputed data and adjusted for missing-data biases, 
which allowed us to compare means over time (table 3 
and figure 1). At 24 months, mean IBS-SSS had 
deteriorated by 14·1 points in the telephone-CBT group 
and by 14·9 points in the web-CBT groups compared 
with the 12-month follow-up, whereas IBS-SSS in the 
TAU group had improved by 7·6 points. These trends of 
12-month follow-up 24-month follow-up Predicted change 
over long–term 
follow–up period
Predicted mean (95% CI) or 
log odds (95% CI)
Odds (95% CI) Predicted mean (95% CI) or 
log odds (95% CI)
Odds (95% CI)
IBS-SSS
Telephone-CBT group 146·9 (122·7 to 171·0) ·· 161·0 (140·2 to 181·9) ·· 14·1
Web-CBT group 173·7 (155·3 to 192·2) ·· 188·6 (169·9 to 207·2) ·· 14·9
TAU group 209·1 (192·5 to 225·8) ·· 201·5 (182·7 to 220·3) ·· –7·6
WSAS
Telephone-CBT group 7·2 (6·0 to 8·5) ·· 7·0 (5·6 to 8·4) ·· –0·2
Web-CBT group 7·8 (6·6 to 9·1) ·· 8·2 (6·9 to 9·5) ·· 0·4
TAU group 10·7 (9·5 to 11·9) ·· 10·1 (8·8 to 11·4) ·· –0·6
HADS
Telephone-CBT group 12·5 (11·4 to 13·5) ·· 12·5 (11·3 to 13·8) ·· 0·0
Web-CBT group 13·0 (12·1 to 14·0) ·· 13·0 (11·7 to 14·3) ·· 0·0
TAU group 15·2 (14·2 to 16·2) ·· 15·7 (14·5 to 16·8) ·· 0·5
PEQ
Telephone-CBT group 1·08 (0·41 to 1·75)* 2·68 (1·37 to 2.95) 1·11 (0·55 to 1·66) 3·02 (1·73 to 5·28) 0·03†
Web-CBT group 0·11 (–0·29 to 0·51) 1·02 (0·52 to 1·12) 0·18 (–0·24 to 0·60) 1·20 (0·79 to 1·82) 0·07†
TAU group –1·16 (–1·59 to –0·72) 0·29 (0·15 to 0·31) –1·01 (–1·47 to –0·55) 0·36 (0·23 to 0·58) 0·15†
Data are predicted mean (95% CI) for IBS-SSS, WSAS, and HADs and log odds (95% CI) and odds (95% CI) for PEQ. Predictions are for sample average values of baseline variables 
(265 for IBS-SSS, 12·5 for WSAS, and 16·4 for HADS) and for the site from which most participants were recruited (general practices in Southampton). IBS-SSS=Irritable Bowel 
Syndrome Symptom Severity Score. CBT=cognitive behavioural therapy. TAU=treatment as usual. WSAS=Work and Social Adjustment Scale. HADS=Hospital Anxiety and 
Depression Scale. PEQ=Patient Enablement Questionnaire. *For the telephone-CBT group at the 12-month follow-up, therapist effects were found to be significant and were 
included in the model; the log odds presented here are conditional effects (conditioned on therapist in the telephone-CBT group). †Difference in log odds.
Table 3: Predicted change in mean outcomes between 12 months and 24 months
Figure 1: Predicted mean IBS-SSS by assessment time point and trial arm
Data are mean (95% CI). Predictions are made from respective analysis models fitted by multiple imputation with 
baseline set to the sample average value (IBS-SSS=265) and for the site from which most participants were 
recruited (general practitioners in Southampton). The possible range for IBS-SSS is 0–500. CBT=cognitive 
behavioural therapy. IBS-SSS=Irritable Bowel Syndrome Symptom Severity Score. TAU=treatment as usual.
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both CBT group participants losing previous gains but 
the TAU group participants improving could possibly 
explain the observed change in the IBS-SSS differences 
between the CBT groups and the TAU group at 
24 months versus 12 months. 
84 (71%) of 119 patients in the telephone-CBT group, 
62 (63%) of 99 in the web-CBT, and 48 (46%) of 105 in the 
TAU group were IBS-SSS responders (ie, participants 
who had a clinically significant change in IBS-SSS 
[≥50 point] from baseline to 24 months; table 1).
The WSAS scores maintained significant improve-
ments in both the telephone-CBT and web-CBT groups 
compared with the TAU group, between 12 months and 
24 months. At 24 months, the mean WSAS score was 
3·1 points (95% CI 1·3–4·9; p<0·001) lower in the 
telephone-CBT group and 1·9 points (0·1 to 3·7; 
p=0·036) lower in the web-CBT group than in the TAU 
group (mean WSAS score 9·7 [SD 8·5]; tables 1, 2). 
Estimated mean WSAS score in all three groups 
remained quite stable in the 12–24-month period (figure 2 
and table 3).
Further ACTIB outcome measures showed significant 
improvement in both therapy groups compared with TAU 
at 24 months (table 2). The mean HADS score was 
3·1 points (95% CI 1·6–4·7) lower in the telephone-CBT 
group (p<0·001) and 2·7 points (1·0–4·4) lower in the web-
CBT group (p=0·002) than in the TAU group. For PEQ 
responders the OR was 8·3 (4·2–16·4; p<0·001) for the 
telephone-CBT versus the TAU group and 3·3 (1·8–6·0; 
p=0·001) for the web-CBT versus the TAU group. For SGA 
there was a problem with data collection at 24 months and 
too few participants completed this outcome measure for 
us to formally analyse the data (table 1).
We assessed participants’ use of additional CBT 
treatments during naturalistic follow-up (table 4). 48 (9%) 
of 558 participants sought any form of CBT for any 
condition between 12 months and 24 months, of whom 
15 (8%) of 186 were in the telephone-CBT group, 13 (7%) 
of 185 in the web-CBT group, and 20 (11%) of 187 in the 
TAU group. Eight (1%) of 558 patients sought IBS-specific 
CBT, of whom three (2%) of 186 were in the telephone-
CBT group, one (1%) of 185 in the web-CBT group, and 
four (2%) of 187 in the TAU group. The proportions of 
participants seeking CBT for any condition in the 
12–24-month period did not differ between groups 
(Fisher’s exact test for telephone-CBT vs TAU, p=0·48; for 
web-CBT vs TAU, p=0·27). Only ten (5%) of 187 participants 
from the TAU group accessed Regul8 despite all TAU 
participants being sent an access link at 12 months. The 
percentages of participants deviating from the treatment 
allocated to them in the trial for any reason (ie, participants 
who did not receive the allocated treatment or who 
received some form of CBT in the follow-up period) are 
shown in table 4.
We also assessed longer-term efficacy of web-CBT and 
telephone-CBT via per-protocol analyses. In our per-
protocol analysis, mean IBS-SSS at 24 months was 
50·0 points (95% CI 24·5–75·5; p<0·001) lower in the 
telephone-CBT group and 51·5 points (23·9–79·0; 
p<0·001) lower in the web-CBT group than in the TAU 
group. Mean WSAS at 24 months 4·1 points (2·2–5·9; 
p<0·001) lower in the telephone-CBT group and 
3·7 points (1·7–5·7; p<0·001) lower in the web-CBT 
group than in the TAU group. In the per-protocol versus 
ITT analyses, mean IBS-SSS decreased by an additional 
9·5 points in the telephone-CBT group and 38·6 points 
in the web-CBT group, and the mean WSAS score 
decreased by additional 1·0 point in the telephone-CBT 
group and 1·8 points in the web-CBT group, compared 
with the TAU group. The web-CBT group was subject to 
higher proportions of non-adherence with therapy than 
the telephone-CBT group (table 4), which might explain 
the larger differences found between efficacy (ie, in the 
per-protocol population) and effectiveness (ie, in the ITT 
population) for the web-CBT group compared with the 
Figure 2: Predicted mean WSAS by assessment time point and trial arm
Data are mean (95% CI). Predictions are made from the respective analysis models fitted by multiple imputation 
with baseline set to the sample average value (WSAS score 12·5) and for the site from which most participants 
were recruited (general practitioners in Southampton). The possible range for WSAS is 0–40. CBT=Cognitive 
behavioural therapy. WSAS=Work and Social Adjustment Scale. TAU=treatment as usual.
0
2·5
5·0
7·5
10·0
12·5
15·0
17·5
20·0
M
ea
n 
W
SA
S 
sc
or
e
3 6 9 12 24
Time (months)
Telephone-CBT group
Web-CBT group
TAU group
15 18 21
Telephone-CBT 
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(n=185)
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(n=187)
All 
(n=558)
12–24 months post-trial follow–up period
Any CBT sought including Regul8 15 (8%) 13 (7%) 20 (11%) 48 (9%)
CBT for IBS sought* 3 (2%) 1 (1%) 4 (2%) 8 (1%)
CBT for other condition sought* 13 (7%) 12 (6%) 12 (6%) 37 (7%)
Regul8 used* 0 (0%) 0 (0%) 10 (5%) 10 (2%)
Trial period (0–12 months)
Non-adherence with allocated treatment 29 (16%) 57 (31%) 0 (0%) 86 (15%)
Whole observation period (0–24 months)
Participants deviating from the treatment 
allocated†
43 (23%) 68 (37%) 20 (11%) 131 (23%)
Data are n (%). CBT=cognitive behavioural therapy. IBS=irritable bowel syndrome. *These treatments are not mutually 
exclusive. Participants were free to seek treatment for any or all categories. †Participants who did not receive the 
allocated treatment or who received some form of CBT in the follow-up period.
Table 4: Additional CBT treatment sought during naturalistic follow-up
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telephone-CBT group. However, these efficacy results 
should be treated with care as they are based on the 
complete cases at 24 months only and are subject 
to selection bias, whereas the multiple-imputation 
effective ness analyses are able to adjust for further 
variables driving the missing data generating process.
At the end of the year following the trial, participants 
were asked to report any adverse events in months 12–24. 
41 adverse events were reported (11 in the telephone-
CBT group, 15 in the web-CBT group, and 15 in the TAU 
group). Of these, eight were reported as gastrointestinal-
related (two in the telephone-CBT group, four in the 
web-CBT group, and two in the TAU group), five were 
psychological (two in the telephone-CBT group, none in 
the web-CBT group, and three in the TAU group), and 
six were musculoskeletal (one in the telephone-CBT 
group, two in the web-CBT group, and three in the TAU 
group). No adverse events were reported as related to 
the intervention.
Discussion
Compared with the TAU group, both telephone-CBT 
and web-CBT intervention groups showed sustained 
improve ments in outcomes at 24 months. However, 
these were reduced in magnitude at 24 months versus 
12 months. Despite this decrease, the ITT analysis 
showed that at 24 months both CBT groups reported 
significantly less impact of IBS on life and the telephone-
CBT group reported significantly greater reductions in 
IBS-SSS than the TAU group. The proportion of patients 
who had a clinically significant change in IBS symptoms 
(IBS-SSS change ≥50 points between baseline and 
24 months) was 71% in the telephone-CBT group and 
63% in the web-based CBT group, compared with 46% 
in the TAU group. In terms of other outcomes, 
reductions in total anxiety and depression (HADS) and 
patient enablement gains (ie, ability to cope with their 
illness; PEQ) in the CBT arms remained strong at 
24 months.
The complete case per-protocol analysis indicated that 
patients who adhered with the CBT interventions 
(as defined in our protocol7) and did not seek additional 
CBT treatments in the 12–24-month period maintained 
significant gains in both IBS-SSS and WSAS outcomes 
at 24 months in both the CBT groups. The difference in 
the ITT and per-protocol analysis was particularly marked 
for the web-CBT group. This difference could be due to 
the proportion of patients who adhered to the prescribed 
CBT being somewhat lower in the web-CBT group than 
that in the telephone-CBT group. Differential adherence 
between the CBT groups might also explain some of the 
differences seen in the outcome measures between the 
CBT groups in the ITT analysis.
This study’s strengths include follow-up of a well 
powered, rigorously conducted RCT with broad inclusion. 
The IBS-specific CBT was based on an explicit theoretical 
model12,20 informing the detailed patient and therapy 
manuals and the web-based CBT (Regul8). Therapists 
were experienced in delivering CBT and trained and 
supervised to deliver IBS-specific CBT. Trial interventions 
had good treatment fidelity8 and were delivered by NHS 
therapists in an NHS setting. We believe this is the first 
large-scale trial of CBT for IBS to publish 24 months 
follow-up data. This longer-term follow-up provides both 
patients and clinicians with valuable information that the 
benefits of CBT for IBS are sustained.
Limitations include the potential for limited external 
validity as people with IBS who are unwilling to consider 
undertaking CBT for IBS are unlikely to have participated 
in the trial. However, we believe that the sample was 
broadly representative of people with IBS, as the age and 
gender was similar between those invited to participate in 
the ACTIB trial and those who were randomly allocated to 
trial groups, although there was little ethnic diversity. The 
proportion of patients who participated in follow-up was 
58% at 24 months, compared with 70% at 12 months. 
Thus, there is potential for the 24-month outcome analyses 
to be affected by missing-data biases. To mitigate against 
this possibility, multiple imputation, which accommodates 
all observed predictors of missingness, was used.
The 12-month results from ACTIB8 and previous 
research6,13,14 have shown face-to-face and telephone-
delivered CBT to be beneficial for IBS, particularly 
immediately after completing treatment. However, a 
Cochrane review6 concluded that it was unclear whether 
the effects were maintained in the longer term. Other 
large published trials4,5 of CBT for IBS report 6 months 
post-randomisation follow-up. For instance, a three-arm 
RCT5 (n=436) compared face-to-face CBT for IBS with 
home-based CBT (minimal-contact CBT) using self-study 
materials and IBS education alone.5 This study showed 
promising results for low-intensity CBT for IBS. 
Improvement was reported at 2 weeks in both their CBT 
arms compared with education alone, and on 
gastroenterologist (but not patient) ratings at 6 months 
on the clinical global impressions improvement scale. 
However, follow-up was limited to 6 months and 
participants were only recruited from tertiary centres and 
did not show significantly greater improvements for CBT 
than education alone on IBS-SSS at any timepoint. 
ACTIB 24-month follow-up showed improvements in 
IBS-SSS and global symptoms (SGA). The gains 
maintained at 24 months are despite having no further 
input from a trial therapist since month 8 (ie, 16 months 
before the 24-month outcome measures were recorded). 
Most of the therapy contact was in the first 3 months 
(two booster sessions were offered at 4 and 8 months) 
and the overall maximum dose of therapy was 8 h for the 
telephone-CBT group and 2·5 h for the web-CBT group. 
In the NHS, therapist-delivered CBT is typically offered 
as 5–20 sessions, so even the higher intensity CBT is at 
the lower end of the typical therapy dose.
Currently, clinicians have few options to offer people 
with refractory IBS, particularly in primary care. This 
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study shows that IBS-specific CBT has the potential to 
provide significant improvement in terms of IBS’s 
impact on life and symptom severity, with ongoing 
benefits at 24 months. Offering both web-CBT and 
telephone-CBT in NHS services such as Improving 
Access to Psychological Therapy could allow many 
patients to gain substantial benefits with web-CBT with 
minimal therapist input while allowing a step-up 
approach to telephone-CBT for those needing additional 
support.
We are planning a future publication on the cost 
effectiveness of telephone-delivered and web-based CBT 
for IBS interventions and also on whether there are 
identifiable moderators and mediators that would 
indicate who is most likely to benefit from CBT for IBS. 
Further research is needed to assess whether telephone-
delivered and web-based CBT can be widely disseminated 
in a non-trial clinical settings.
This study reinforces NICE guidance3 that patients 
with refractory IBS should be offered CBT for IBS, which 
is currently not widely available. Our results show that 
both telephone therapist-delivered and web-based CBT 
for IBS can provide long-term benefits.
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